Sign in
CompletedNo phase

Prenatal Dex Study

Key facts

Who runs it
Hospices Civils de Lyon
Where
France10 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
354 people enrolled
Started
4 Oct 2016
Ended
13 Jun 2025
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Neuropsychological and cognitive assessment
Record updated
11 December 2025

Who can take part

Age
6 years to 15 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Groups D+1, D+2, D-1 and D-2
  • Male or female
  • Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
  • Age: 6 to 15 years (at the time of inclusion)
  • The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
  • Subject with health insurance; Group D-3 (Schoolchildren)
  • Male or female
  • With no connection with Congenital Adrenal Hyperplasia
  • Age: 6 to 15 years (at the time of inclusion)
  • The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
  • Subject with health insurance

Who cannot take part

  • Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child
  • Patient/Subject with another genetic disease
  • Patient/Subject with known neuropsychology disease(s)
  • For all groups :

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.

The 5 groups in the trial

  • Group D+ 1Treatment being tested

    Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.

    Treatment: Neuropsychological and cognitive assessment

  • Group D+ 2Treatment being tested

    Girls and boys affected by CAH and treated in utero by Dexamethasone.

    Treatment: Neuropsychological and cognitive assessment

  • : Group D - 1Existing treatment, for comparison

    Girls and boys not affected by CAH and not treated in utero by Dexamethasone.

    Treatment: Neuropsychological and cognitive assessment

  • Group D - 2Existing treatment, for comparison

    Girls and boys affected by CAH and not treated in utero by Dexamethasone.

    Treatment: Neuropsychological and cognitive assessment

  • Group D - 3Other group

    Girls and boys enrolled in school closed to Lyon

    Treatment: Neuropsychological and cognitive assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicentric Evaluation of in Utero Dexamethasone (DEX) on the Cognitive Development of Children at Risk of Congenital Adrenal Hyperplasia
Record updated
11 December 2025